Filter by
Selections
January 25, 2021
Arrowhead Pharmaceuticals Files IND for Phase 2b Study of ARO-ANG3 for Treatment of Mixed Dyslipidemia
Read MoreDecember 7, 2020
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
Read MoreNovember 13, 2020
Arrowhead Presents New Clinical Data on Cardiometabolic Pipeline at AHA 2020
Read MoreNovember 13, 2020